IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

1-4 of 4

• 

  RestartResume

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  RestartResume

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  I. Paul Singh, MD

  I. Paul Singh, MD

• 

  RestartResume

  Comparing 5-Year Corneal Endothelial Safety of Multiple MIGS Devices

  RestartResume

  Comparing 5-Year Corneal Endothelial Safety of Multiple MIGS Devices

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  Comparing 5-Year Corneal Endothelial Safety of Multiple MIGS Devices

  Arsham Sheybani, MD

  Arsham Sheybani, MD

• 

  RestartResume

  Evaluating Novel Crosslinked Hyaluronate Canalicular Gel Occlusive for DED

  RestartResume

  Evaluating Novel Crosslinked Hyaluronate Canalicular Gel Occlusive for DED

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  Evaluating Novel Crosslinked Hyaluronate Canalicular Gel Occlusive for DED

  Brandon D. Ayres, MD

  Brandon D. Ayres, MD

• 

  RestartResume

  Patient-Reported Outcomes After Switching to or Starting Preservative-Free Latanoprost

  RestartResume

  Patient-Reported Outcomes After Switching to or Starting Preservative-Free Latanoprost

  IJC Recap: MIGS and the Cornea, a New Take on Punctal Occlusion, and a Preservative-Free Latanoprost Formulation

  Patient-Reported Outcomes After Switching to or Starting Preservative-Free Latanoprost

  Jason Bacharach, MD

  Jason Bacharach, MD